O14 Rituximab objective outcome measures trial in SLE (ROOTS): outcomes of randomised and rescue rituximab therapy in a double-blind randomised placebo-controlled trial
Khaled Mahmoud(University of Leeds), Edward M Vital(University of Leeds), E. Hensor(University of Leeds), Md Yuzaiful Md Yusof(University of Leeds), Sarah Brown(University of Leeds), Michelle Wilson(University of Leeds)
Cited by 3
Related Papers
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial
|The Lancet|2010|640
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial
|The Lancet Rheumatology|2019|478